Harrow, Inc. (HROW)
NASDAQ: HROW · Real-Time Price · USD
41.93
-0.66 (-1.55%)
At close: Jan 29, 2026, 4:00 PM EST
41.70
-0.23 (-0.55%)
After-hours: Jan 29, 2026, 4:14 PM EST
Harrow Revenue
Harrow had revenue of $71.64M in the quarter ending September 30, 2025, with 45.44% growth. This brings the company's revenue in the last twelve months to $250.04M, up 47.83% year-over-year. In the year 2024, Harrow had annual revenue of $199.61M with 53.32% growth.
Revenue (ttm)
$250.04M
Revenue Growth
+47.83%
P/S Ratio
6.20
Revenue / Employee
$654,560
Employees
382
Market Cap
1.55B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 199.61M | 69.42M | 53.32% |
| Dec 31, 2023 | 130.19M | 41.60M | 46.95% |
| Dec 31, 2022 | 88.60M | 16.12M | 22.24% |
| Dec 31, 2021 | 72.48M | 23.61M | 48.30% |
| Dec 31, 2020 | 48.87M | -2.29M | -4.48% |
| Dec 31, 2019 | 51.17M | 9.79M | 23.67% |
| Dec 31, 2018 | 41.37M | 14.60M | 54.52% |
| Dec 31, 2017 | 26.77M | 6.83M | 34.26% |
| Dec 31, 2016 | 19.94M | 10.23M | 105.25% |
| Dec 31, 2015 | 9.72M | 8.06M | 485.30% |
| Dec 31, 2014 | 1.66M | -8.34M | -83.40% |
| Dec 31, 2013 | 10.00M | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2005 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bausch Health Companies | 10.03B |
| Perrigo Company | 4.28B |
| Phibro Animal Health | 1.40B |
| Evotec SE | 887.40M |
| ANI Pharmaceuticals | 826.88M |
| Collegium Pharmaceutical | 757.07M |
| BioCryst Pharmaceuticals | 599.82M |
| Alvotech | 573.35M |
HROW News
- 6 days ago - Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update - Seeking Alpha
- 17 days ago - Harrow: Flirting With Missing 2025 Revised Guidance - Seeking Alpha
- 7 weeks ago - Undercovered Dozen: USA Rare Earth, Santacruz Silver, Western Midstream, Visa And More - Seeking Alpha
- 2 months ago - Harrow to Present at Two Investor Conferences in December - GlobeNewsWire
- 2 months ago - Harrow Announces Closing of Acquisition of Melt Pharmaceuticals - GlobeNewsWire
- 2 months ago - Harrow, Inc. (HROW) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Harrow Announces Third Quarter 2025 Financial Results - GlobeNewsWire
- 3 months ago - Harrow Q3 Earnings Preview: This Business Has Eye-Popping Potential - Seeking Alpha